-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, I6hTruS1CX6cD5NJe09PmfdX4kEYrHOyLocrV9gaovjk0hUpKY9KvsP3ZkAb9AXJ 18Mb23SCr/POV5qkvKn5fw== 0000922423-99-000514.txt : 19990413 0000922423-99-000514.hdr.sgml : 19990413 ACCESSION NUMBER: 0000922423-99-000514 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 19990412 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: SYNAPTIC PHARMACEUTICAL CORP CENTRAL INDEX KEY: 0000884939 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 222859704 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: SEC FILE NUMBER: 005-45417 FILM NUMBER: 99591932 BUSINESS ADDRESS: STREET 1: 215 COLLEGE RD CITY: PARAMUS STATE: NJ ZIP: 07652 BUSINESS PHONE: 2012611331 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: GILDER GAGNON HOWE & CO LLC CENTRAL INDEX KEY: 0000902464 STANDARD INDUSTRIAL CLASSIFICATION: [] IRS NUMBER: 133174112 STATE OF INCORPORATION: NY FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: STREET 1: 1775 BROADWAY STREET 2: 26TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10019 BUSINESS PHONE: 2127652500 MAIL ADDRESS: STREET 1: 1775 BROADWAY STREET 2: 26TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10019 FORMER COMPANY: FORMER CONFORMED NAME: GILDER GAGNON HOWE & CO DATE OF NAME CHANGE: 19930428 SC 13G/A 1 SCHEDULE 13G FINAL AMENDMENT SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Under the Securities Exchange Act of 1934 SCHEDULE 13G (Final Amendment) INFORMATION STATEMENT PURSUANT TO RULES 13d-1 AND 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Synaptic Pharmaceutical Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 87156R109 (CUSIP Number) March 31, 1999 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: |X| Rule 13d-1(b) |_| Rule 13d-1(c) \ |_| Rule 13d-1(d) Page 1 of 6 Pages SCHEDULE 13G CUSIP No. Page 2 of 6 Pages - -------------------------------------------------------------------------------- 1) NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Gilder Gagnon Howe & Co. LLC 13-3174112 - -------------------------------------------------------------------------------- 2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [ ] (b) [ ] - -------------------------------------------------------------------------------- 3) SEC USE ONLY - -------------------------------------------------------------------------------- 4) CITIZENSHIP OR PLACE OF ORGANIZATION New York - -------------------------------------------------------------------------------- 5) SOLE VOTING POWER None NUMBER ------------------------------------------------- OF 6) SHARED VOTING POWER SHARES None BENEFICIALLY ------------------------------------------------- OWNED BY 7) SOLE DISPOSITIVE POWER EACH None REPORTING ------------------------------------------------- PERSON 8) SHARED DISPOSITIVE POWER WITH 2,000 - -------------------------------------------------------------------------------- 9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 2,000 - -------------------------------------------------------------------------------- 10) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES [ ] - -------------------------------------------------------------------------------- 11) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 0.0% - -------------------------------------------------------------------------------- 12) TYPE OF REPORTING PERSON BD - -------------------------------------------------------------------------------- Page 2 of 6 Pages Schedule 13G Item 1(a). Name of Issuer: Synaptic Pharmaceutical Corporation Item 1(b). Address of Issuer's Principal Executive Offices: 215 College Road Paramus, NJ 07652 Item 2(a). Name of Person Filing: Gilder Gagnon Howe & Co. LLC Item 2(b). Address of Principal Business Office or, if None, Residence: 1775 Broadway, 26th Floor New York, NY 10019 Item 2(c). Citizenship: New York Item 2(d). Title of Class of Securities: Common Stock Item 2(e). CUSIP Number: 87156R109 Item 3. If this statement is filed pursuant to ss.ss.240.13D-1(B), or 240.13D-2(B) or (C), check whether the person filing is a: (a)|X| Broker or Dealer Registered Under Section 15 of the Act (15 U.S.C. 78o) (b)|_| Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c) (c)|_| Insurance Company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c) (d)|_| Investment Company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8) (e)|_| Investment Adviser in accordance with ss.240.13d-1(b)(1)(ii)(E) Page 3 of 6 Pages (f)|_| Employee benefit plan or endowment fund in accordance with ss.240.13d-1(b)(1)(ii)(F) (g)|_| Parent Holding Company or control person in accordance with ss.240.13d-1(b)(ii)(G) (h)|_| Savings Association as defined in ss.3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813) (i)|_| Church plan that is excluded from the definition of an investment company under ss.3(c)(15) of the Investment Company Act of 1940 (15 U.S.C. 80a-3) (j)|_| Group, in accordance with ss.240.13d-1(b)(ii)(J) Item 4. Ownership. (a) Amount beneficially owned: 2,000 (b) Percent of class: 0.0% (c) Number of shares as to which such person has: (i) Sole power to vote or to direct the vote: None (ii) Shared power to vote or to direct the vote: None (iii) Sole power to dispose or to direct the disposition of: None (iv) Shared power to dispose or to direct the disposition of: 2,000 The shares reported are held in customer accounts over which members and/or employees of the Reporting Person have discretionary authority to dispose of or direct the disposition of the shares. Item 5. Ownership of Five Percent or Less of a Class. This statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities. Page 4 of 6 Pages Item 6. Ownership of More than Five Percent on Behalf of Another Person. None. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company. Not applicable. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certification. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired in the ordinary course of business and were not acquired for the purpose of and do not have the effect of changing or influencing the control of the issuer of such securities and were not acquired in connection with or as a participant in any transaction having such purposes or effect. Page 5 of 6 Pages SIGNATURE After reasonable inquiry and to the best knowledge and belief of the undersigned, the undersigned certifies that the information set forth in this Statement is true, complete and correct. April 12, 1999 -------------- Date /s/ Walter Weadock ------------------ Signature Walter Weadock, Member Name/Title Page 6 of 6 Pages -----END PRIVACY-ENHANCED MESSAGE-----